



BIOMM SA  
Public Company  
CNPJ/MF No. 04.752.991/0001-10  
NIRE No. 31.300.016.510

### **MATERIAL FACT**

**BIOMM S.A.** ("Company" or "Biommm"), in compliance with the provisions of CVM Resolution No. 44 of August 23, 2021, hereby informs its shareholders and the market in general, continuing the Material Fact dated on January 6, 2021 and the Material Fact dated on April 13, 2021, which was published in the Federal Official Gazette (DOU), on July 18, 2022, the decision to make the current temporary price of its product Ghemaxan® (enoxaparin sodium) definitive, throughout the Brazilian territory.

Resolution CTE/CMED nº 4/2021, from March 25, 2021, established interim prices for the sale of medicines intended for the treatment of Covid-19, among which is Ghemaxan®, a medicine used for the treatment and prophylaxis of thromboembolism that has been used in the treatment of patients with Covid-19.

The decision published today in the DOU, reverts the temporary price decision and makes the price of Ghemaxan® final.

Nova Lima/MG, July 18, 2022.

**Mirna Santiago Vieira**  
Chief Financial and Investor Relations Officer